Project Grant HT94252510581

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $179,988 to the University of Utah to conduct research on the role of dietary lipids in accelerating breast cancer tumor growth, particularly in the context of obesity. The key objectives are to: Determine if breast cancer cells preferentially utilize dietary lipids over glucose in lipid-rich environments, such as those found in obesity. Trace the metabolic fate of...

This $159,183 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research investigating the role of diet and the ACSS2 enzyme in the metabolic and epigenetic regulation of colorectal cancer. The primary objectives are to determine how the dietary components acetate and fructose interact to affect colorectal cancer growth and acetyl-CoA metabolism, as well as identify the mechanisms by which acetate, fructose, and ACSS2 regulate...

This $524,419 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate the molecular basis of fatty acid synthase (FASN) inhibition and its impact on overcoming resistance to PARP inhibitors (PARPi) in triple-negative breast cancer (TNBC). The project will: 1) determine the molecular mechanism by which proton pump inhibitors (PPIs) inhibit FASN, 2) elucidate how FASN contributes to PARPi resistance by regulating PARP1 and BRCA1...

This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $521,579 to The University of Texas Southwestern Medical Center to conduct research aimed at understanding the molecular mechanisms driving lung metastasis in clear cell renal cell carcinoma (CCRCC), a common and highly lethal form of kidney cancer. The key research objectives are to: 1) Characterize the functional role of the hepatic leukemia factor (HLF) gene in promoting CCRCC lung...

This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $122,834 to Duke University to investigate how inhibiting the ABL kinase enzyme can sensitize small cell lung cancer (SCLC) cells to metabolic dysregulation, leading to cell death. The research aims to determine how ABL kinases mediate metabolic function, the mechanism of metabolic dysregulation following ABL inhibition, and the extent to which combining ABL kinase...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $130,607 to the University of California, Los Angeles (UCLA) to investigate the role of peroxisomal PEX family proteins in hepatic bile acid and lipid metabolism. The research aims to dissect how the loss of PEX6 and PEX14 proteins impacts lipid homeostasis and inter-organelle crosstalk...

This Project Grant award, titled "METABOLIC CONTROL OF MALIGNANT FATES IN LUNG CANCER", is funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $730,400 award, with a period of performance from December 1, 2024 to November 30, 2029, will support research conducted by the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization in New York, NY. The research aims to determine how specific...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the efficacy of immunotherapy against metastatic colorectal cancer (MCRC). The $640,583 grant awarded to Cold Spring Harbor Laboratory will fund research to activate the PPARD-CPT1A axis in CD8+ T cells, which is expected to boost the fitness and anti-tumor activity of these immune cells within the MCRC tumor microenvironment. The 5-year project will delineate the underlying...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the role of the protein angiopoietin-like 4 (ANGPTL4) in clear cell renal cell carcinoma (ccRCC) and its potential as a therapeutic target. The 5-year, $371,905 award to the University of Florida aims to define ANGPTL4's functions in the ccRCC tumor microenvironment, assess the efficacy of combining anti-ANGPTL4 antibodies with immune...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on investigating the mechanisms of renal lipotoxicity and its contribution to chronic kidney disease (CKD). The total funding amount is $128,286.00, with an award date of December 16, 2024 and an ultimate completion date of June 30, 2027. The primary goals of the research are to...